Document is current
Any future updates will be listed below
-
Authors
Blanchard, Tatiana
Faridi, Pouya
Xu, Chong
Bear, Adham S.
Rasool, Reyaz ur
Huang, Grace
Lim, Terry C. C.
Ayala, Rochelle
Gabunia, Khatuna
Ji, Mei
Posey, Avery D. Jr
Scholler, John
Asangani, Irfan A.
Purcell, Anthony W.
Linette, Gerald P.
June, Carl H.
Carreno, Beatriz M.
-
Funding
Funding for this research was provided by:
National Institutes of Health (T32CA099140, K12CA076931, U54CA244711, U54CA244711, U54CA244711)
Victorian Cancer Agency (2001870)
Cancer Australia
Australian Lions Childhood Cancer Research Foundation
Sarcoma Foundation of America
American Cancer Society
National Health and Medical Research Council (2016596)
Parker Institute for Cancer Immunotherapy
- License Information
-
More Information
Article History
Received: 22 November 2024
Accepted: 1 April 2025
First Online: 15 April 2025
Declarations
:
: T.B, I.A.A., G.P.L., and B.M.C. are inventors on a patent (63/516,178) related to the targeting of LOXHD1 for immunotherapy entitled “Compositions and Methods for Targeting LOXHD1-Associated Disease”. All other authors have no competing interest to declare.
